Next Generation Cancer Vaccines—Make It Personal!

Terbuch, Angelika; Lopez, Juanita

doi:10.3390/vaccines6030052

Cited by 24 publications

(17 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunosuppressive TME is a major cause for failure of cancer vaccine immunotherapy (20). Therefore, we next examined whether codelivery of PD-L1 siRNA and IL-2 pDNA could modulate the immunosuppressive TME to restore the efficacy of a tumor vaccine in HCC.…”

Section: Pd-l1 Sirna and Il-2 Pdna Codelivered By Tt-ldcp Nps Reprogrmentioning

confidence: 99%

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

et al. 2020

View full text Add to dashboard Cite

While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader application of cancer immunotherapy. Here, we report a combinatorial immunotherapy approach that uses a highly efficient and tumor-selective gene carrier to improve anticancer efficacy and circumvent the systemic toxicity. In this study, we engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDCP) nanoparticles (NPs) with thymine-functionalized dendrimers that exhibit not only enhanced gene delivery capacity but also immune adjuvant properties by activating the stimulator of interferon genes (STING)–cGAS pathway. TT-LDCP NPs delivered siRNA against immune checkpoint ligand PD-L1 and immunostimulatory IL-2–encoding plasmid DNA to hepatocellular carcinoma (HCC), increased tumoral infiltration and activation of CD8+ T cells, augmented the efficacy of cancer vaccine immunotherapy, and suppressed HCC progression. Our work presents nanotechnology-enabled dual delivery of siRNA and plasmid DNA that selectively targets and reprograms the immunosuppressive tumor microenvironment to improve cancer immunotherapy.

show abstract

Section: Pd-l1 Sirna and Il-2 Pdna Codelivered By Tt-ldcp Nps Reprogrmentioning

confidence: 99%

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These patients will require an induction or direct administration of tumor-specific T cells in order for the cells to reach the tumors [104]. Recent studies suggested that neoantigens, which arise as a result of genetic mutations in the tumor, can effectively eliminate tumor cells [105,106]. However, neoantigens are not suited for use as universal antigens because they differ among patients and cancer types.…”

Section: Htert-targeted Cancer Immunotherapy: Future Perspectivesmentioning

confidence: 99%

Telomerase-Targeted Cancer Immunotherapy

Mizukoshi

Kaneko

2019

IJMS

View full text Add to dashboard Cite

Telomerase, an enzyme responsible for the synthesis of telomeres, is activated in many cancer cells and is involved in the maintenance of telomeres. The activity of telomerase allows cancer cells to replicate and proliferate in an uncontrolled manner, to infiltrate tissue, and to metastasize to distant organs. Studies to date have examined the mechanisms involved in the survival of cancer cells as targets for cancer therapeutics. These efforts led to the development of telomerase inhibitors as anticancer drugs, drugs targeting telomere DNA, viral vectors carrying a promoter for human telomerase reverse transcriptase (hTERT) genome, and immunotherapy targeting hTERT. Among these novel therapeutics, this review focuses on immunotherapy targeting hTERT and discusses the current evidence and future perspectives.

show abstract

“…In contrast to the above strategies, tumor vaccines, which are designed to expand tumor-specific T-cell responses through enhanced active immunization, have long been anticipated as probable effective cancer immunotherapy [ 20 , 21 ]. The antigen categories of the tumor vaccines are varied [ 22 , 23 ], among which, whole tumor cell-based vaccines have been employed in numerous studies over the past decade, which can offer several advantages over subunit and peptide vaccines [ 24 , 25 ], and hundreds of them were tested in clinical trials to date [ [26] , [27] , [28] ]. Repeated freeze-thaw and irradiation methods are commonly used to prepare whole tumor cell vaccines [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure

Zhou

Peng

Hao

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

In recent years, Non-Hodgkin lymphoma (NHL) has been one of the most fast-growing malignant tumor diseases. NHL poses severe damages to physical health and a heavy burden to patients. Traditional therapies (chemotherapy or radiotherapy) bring some benefit to patients, but have severe adverse effects and do not prevent relapse. The relevance of emerging immunotherapy options (immune-checkpoint blockers or adoptive cellular methods) for NHL remains uncertain, and more intensive evaluations are needed. In this work, inspired by the idea of vaccination to promote an immune response to destroy tumors, we used a biomaterial-based strategy to improve a tumor cell-based vaccine and constructed a novel vaccine named Man-EG7/CH@CpG with antitumor properties. In this vaccine, natural tumor cells are used as a vector to load CpG-ODN, and following lethal irradiation, the formulations were decorated with mannose. The study of the characterization of the double-improved vaccine evidenced the enhanced ability of DCs targeting and improved immunocompetence, which displayed an antitumor function. In the lymphoma prevention model, the Man-EG7/CH@CpG vaccine restrained tumor formation with high efficiency. Furthermore, unlike the non-improved vaccine, the double-improved vaccine elicited an enhanced antitumor effect in the lymphoma treatment model. Next, to improve the moderate therapeutic effect of the mono-treatment method, we incorporated a chemotherapeutic drug (doxorubicin, DOX) into the process of vaccination and devised a combination regimen. Fortunately, a tumor inhibition rate of ~85% was achieved via the combination therapy, which could not be achieved by mono-chemotherapy or mono-immunotherapy. In summary, the strategy presented here may provide a novel direction in the establishment of a tumor vaccine and is the basis for a prioritization scheme of immuno-chemotherapy in enhancing the therapeutic effect on NHL.

show abstract

Next Generation Cancer Vaccines—Make It Personal!

Cited by 24 publications

References 106 publications

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

Telomerase-Targeted Cancer Immunotherapy

The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure

Contact Info

Product

Resources

About